Final week, the Meals and Drug Administration (FDA) stated Novo Nordisk A/’ NVO semaglutide merchandise, together with Wegovy and Ozempic, are not in scarcity.
Semaglutide injection merchandise had been first added to the FDA’s drug scarcity listing for Wegovy in March 2022 and Ozempic in August 2022.
A lawsuit filed by the compounding teams Outsourcing Services Affiliation (OFA) and North American Customized Laboratories, doing enterprise as FarmaKeio Superior Customized Compounding, challenges the FDA’s choice to take away semaglutide from the drug scarcity listing.
Additionally Learn: Novo Nordisk Sues Singapore-Based mostly KBP Biosciences Over Alleged Information Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages
The plaintiffs argue that this motion was arbitrary, illegal, and detrimental to sufferers who depend on compounded semaglutide for kind 2 diabetes, weight problems, and heart problems.
The lawsuit highlights that even the producer of FDA-approved semaglutide acknowledged in its earnings launch that offer points and drug shortages had been ongoing.
Regardless of this, the FDA proceeded with its choice with out participating in a proper notice-and-comment rulemaking course of, which plaintiffs argue violates the Administrative Process Act (APA).
The APA requires federal companies to offer public discover, solicit enter from stakeholders, and provide reasoned explanations for regulatory actions.
In December, Novo Nordisk submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks Checklist, a registry of gear that outsourcing amenities could use in drug compounding.
The petition argues that FDA-approved liraglutide-based merchandise, Victoza, Saxenda, and Xultophy, meet affected person wants with out requiring further compounded variations, which Novo Nordisk contends pose vital security and efficacy dangers.
Final yr, the FDA decided that the Eli Lilly And Co’s LLY tirzepatide injection scarcity had been resolved.
The compounding teams filed a criticism alleging that eradicating the drug from the scarcity listing is predicated solely on the producer’s manufacturing capabilities.
In January, Eli Lilly filed a movement to intervene as a defendant in a case in opposition to the FDA introduced by the Outsourcing Services Affiliation and FarmaKeio Customized Compounding.
Value Motion: LLY inventory is up 1.22% at $912.79 on the final test on Wednesday.
Learn Subsequent:
Picture by way of Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
